ChAdV68 S TCE
Alternative Names: ChAdV68-S-TCE; GRT-C909Latest Information Update: 28 Apr 2024
At a glance
- Originator Gritstone bio
- Developer Gritstone bio; National Institute of Allergy and Infectious Diseases
- Class COVID-19 vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in USA (IM, Injection)
- 15 Sep 2023 Gritstone Oncology and the National Institute of Allergy and Infectious Diseases complete the phase I CORAL-NIH trial in COVID-2019 infections (Prevention, In adults, In the elderly) in USA (IM, Injection) (NCT04776317)
- 19 Dec 2022 Gritstone bio has patent protection for antigen-encoding samRNA vectors and its applicability across candidates in oncology and infectious disease in USA